Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men with Castration-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2019
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 25 Apr 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 31 Aug 2018 Biomarkers information updated
- 22 Nov 2017 Status changed from recruiting to active, no longer recruiting.